2. MH MH Malignant Hyperthermia Objectives Things to know and do: Participants will: 1. be able to explain the: pathophysiology, clinical presentations, testing for and management of malignant hyperthermia and the MHS patient 2. be able to explain the significance of MMR and its management. 3. keep MH somewhere in mind as they monitor patients, and not hesitate to give dantrolene. 4. easily correctly answer the questions in the MH Quiz .
3. MH MH “ If any institution does not feel it can manage the MHS child then they should not be anaesthetising any children at all, since it is not the identified child with a nontriggering technique who will cause grief, but the undiagnosed child given a trigger.” Helen Holtby M.B.,B.S. Director of Cardiovascular Anaesthesia Hospital for Sick Children Toronto, Canada PAC List, 10 Dec 04 Malignant Hyperthermia
4. MH MH pharmacogenetic hypermetabolic state of skeletal muscle induced by inhalational anesthetics or succinylcholine (and maybe stress/exercise)
11. Incidence - Current Concepts Clinically based information: One in 20,000 to 50,000 anesthetics depending on drugs, population Molecular Genetics based information: MH trait in 1 in 2,000-3,000 patients. Low penetrance
13. MH MH Normal excitation-contraction coupling ACh at NMJ depolarizes sarcolemma SR (RYR) releases Ca Ca + troponin actin-myosin slide ATP hydrolyzed SR (RYR?) re-uptake of Ca